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Chorea is a hyperkinetic movement disorder resulting from dysfunction of striatal medium spiny neurons (MSNs), which form themain
output projections from the basal ganglia. Here, we used whole-exome sequencing to unravel the underlying genetic cause in three
unrelated individuals with a very similar and unique clinical presentation of childhood-onset chorea and characteristic brain MRI
showing symmetrical bilateral striatal lesions. All individuals were identified to carry a de novo heterozygous mutation in PDE10A
(c.898T>C [p.Phe300Leu] in two individuals and c.1000T>C [p.Phe334Leu] in one individual), encoding a phosphodiesterase highly
and selectively present in MSNs. PDE10A contributes to the regulation of the intracellular levels of cyclic adenosine monophosphate
(cAMP) and cyclic guanosine monophosphate (cGMP). Both substitutions affect highly conserved amino acids located in the regulatory
GAF-B domain, which, by binding to cAMP, stimulates the activity of the PDE10A catalytic domain. In silico modeling showed that the
altered residues are located deep in the binding pocket, where they are likely to alter cAMP binding properties. In vitro functional studies
showed that neither substitution affects the basal PDE10A activity, but they severely disrupt the stimulatory effect mediated by cAMP
binding to the GAF-B domain. The identification of PDE10A mutations as a cause of chorea further motivates the study of cAMP
signaling in MSNs and highlights the crucial role of striatal cAMP signaling in the regulation of basal ganglia circuitry. Pharmacological
modulation of this pathway could offer promising etiologically targeted treatments for chorea and other hyperkinetic movement
disorders.Movement disorders comprise a large clinically and genet-
ically heterogeneous group of disorders, which can be sub-
divided into various clinical entities, including dystonia
and chorea. Although monogenic causes are overall rare,
mutations in greater than >200 genes are known to cause
either an isolated movement disorder or a syndromic form
of movement disorders.1–3 However, in total, mutations in
these genes only explain a small proportion of cases, sug-
gesting that mutations in more genes await discovery.
Chorea is a hyperkinetic movement disorder clinically
characterized by continuous and brief involuntary
movements, which flow from one body part to another
and are unpredictable in terms of timing, speed, and
direction. Chorea is a major feature of several inherited
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form the main output projections from the basal ganglia,
is considered to underlie the pathophysiology of the
choreic movements.5
We have identified three European-descent individuals
affected by a similar childhood-onset movement disorder
predominantly characterized by chorea and bilateral stria-
tal abnormalities on cerebral MRI. The main clinical and
radiological features of the three individuals are presented
in Table 1. In brief, all three individuals presented in child-
hood (age of onset between 5 and 10 years) with a scarcely
progressive movement disorder dominated by chorea.
Developmental milestones were normal, and there were
no other major neurological features, in particular intellec-
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Table 1. Genetic, Clinical, and Radiological Findings of Individuals with PDE10A Mutations
Individual 1 Individual 2 Individual 3
Age at most recent clinical
examination
11 years 22 years 60 years
Gender male female female
Descent European (Dutch) European (British) European (British)
CADD scorea 31.0 28.7 28.7
PDE10A Mutation
Genomic position
(GRCh37)
chr6: 165,829,768 A>G chr6: 165,832,223 A>G chr6: 165,832,223 A>G
cDNA (GenBank:
NM_001130690.2)
c.1000T>C c.898T>C c.898T>C
Protein p.Phe334Leu p.Phe300Leu p.Phe300Leu
Inheritance de novo de novo de novob
Neurology
Developmental
milestones
normal normal normal
Cognition normal normal normal
Chorea (age of onset) þ (5) þ (8) þ (5)
Other no anxiety adult-onset parkinsonism
MRI
Bilateral striatal
hyperintensities
þ þ þ
Bilateral striatal swelling þ  
Restriction of diffusion þ  NA
Bilateral striatal atrophy  þ þ
Abbreviations are as follows: þ, present; , absent; and NA, not available.
aA scoreR 20 indicates that the variant is predicted to be the among the 1% most deleterious substitutions in the protein-coding parts of the human genome.
bHaplotype analysis in unaffected siblings suggests the de novo occurrence of the mutation in individual 3.features and the absence of a significant progression of
symptoms, a diagnosis of benign hereditary chorea (BHC
[MIM: 118700])6 was initially considered. However, within
the striatum in all three individuals, brain MRI consis-
tently showed bilateral T2 hyperintensity (Figure 1), which
is an atypical finding for BHC.
It is noteworthy that MRI of individual 1 (II-1 in
Figure 2A; aged 11 years when scanned) showed slight
swelling of the striata (Figure 1A) together with restricted
diffusion (Figures 1B and 1C), suggesting an active disease
process. Conversely, MRI of individual 2 (II-1 in Figure 2A;
aged 22 years when scanned) demonstrated modest atro-
phy of the putamina (Figure 1D) and normal diffusion (Fig-
ures 1E and 1F), suggesting a more advanced stage of dis-
ease. MRI of individual 3 (II-8 in Figure 2A; aged 53 years
when scanned) was markedly degraded by movement
artifacts but also showed T2 hyperintensity within the
posterolateral putamina (Figure S1A), although it was less
dramatic than in the two younger individuals. Interest-
ingly, individual 3, who is currently 60 years old, devel-
oped levodopa-responsive parkinsonism with freezing
and falls in the fifth decade. Imaging of the density of stria-764 The American Journal of Human Genetics 98, 763–771, April 7, 2tal dopamine reuptake transporters (i.e., with DaTscan)
was bilaterally abnormal, consistent with nigrostriatal
degeneration (Figure S1B).
The homogeneous clinical and radiological appearance
of these individuals was suggestive of a common genetic
entity. Yet, extensive genetic and biochemical diagnostic
work-up—focused on a wide spectrum of genetic diseases,
including BHC, metabolic disorders, and mitochondrial
diseases—was unrevealing.
Next, whole-exome sequencing (WES) was performed in
all three individuals, as well as in the unaffected parents of
individuals 1 and 2. The study was approved by the local
ethics committees (Commissie Mensgebonden Onderzoek
Arnhem-Nijmegen of Radboud University Medical Center
for individual 1 under the realm of diagnostic exome
sequencing and University College London Hospitals proj-
ect 06/N076 for individuals 2 and 3). Written informed
consent was obtained for all individuals, after which
DNA was extracted from peripheral lymphocytes accord-
ing to standard protocols. WES was performed as previ-
ously described.7,8 In brief, exomes were enriched with
either the Agilent SureSelectXT Human All Exon 50 Mb016
Figure 1. MRI Features Associated with
Dominant PDE10A Mutations
Axial MRI of individuals 1 (A–C) and 2 (D–
F). T2-weighted imaging (A and D) and
diffusion-weighted imaging (DWI; B and
E) showed increased signal intensity
within the striatum. In individual 1, the
putamen and caudate nucleus appeared
slightly swollen (A), and high signal on
DWI (B) was confirmed to represent
abnormal restricted diffusion on the ADC
map (C). In individual 2, the abnormal
signal was principally located in the post-
ero-lateral putamina, which also appeared
atrophic (D). There was no corresponding
restriction of diffusion on the ADC map
(F), and appearances suggested a more
chronic disease stage.Kit (individual 1) or Illumina’s Nextera Rapid Capture (in-
dividuals 2 and 3) and sequenced on SOLiD 5500XL (indi-
vidual 1) or a HiSeq 3000 (individuals 2 and 3) to an
average sequence depth of 913; on average, 89% of targets
were covered at least 203. Subsequently, variants were
called and annotated with a custom in-house diagnostic
pipeline7 (individual 1) or ANNOVAR9 (individuals 2
and 3). Given the sporadic occurrence of the phenotypes,
filtering of variants focused on de novo dominant or reces-
sive mutations (Figure 2A). Under the assumption that
all three individuals would harbor a mutation in the
same gene, we determined the overlap for putatively
damaging mutations (defined as nonsense, frameshift,
canonical splice-site, or predicted damaging missense
mutations on the basis of CADD scores10 > 20) with a
minor allele frequency < 1% in the Exome Aggregation
Consortium (ExAC) Browser11 and an in-house database
containing >10,000 individuals.
We identified only a single gene, PDE10A (MIM 610652;
GenBank: NM_001130690.2), containing a variant in all
three individuals. In individual 1, the heterozygous
variant c.1000T>C was identified and predicted to result
in p.Phe334Leu. Individuals 2 and 3 carried the same het-
erozygous variant, c.898T>C, which is predicted to result
in p.Phe300Leu. Notably, the family-based sequencing
approach of individuals 1 and 2 directly indicated
that both PDE10A mutations had occurred de novo
(Figure 2A). The parents of individual 3 are deceased, but
the DNA of six unaffected siblings was available for testing,
and none of them harbored the mutation. Further haplo-
type analysis using three microsatellites spanning the
PDE10A locus identified the four parental haplotypes and
revealed that the individual harboring the mutation shares
one of the haplotypes with two siblings and shares the
other with three other siblings, strongly suggesting a de
novo occurrence of the mutation in this individual as
well (Figure 2A and Figure S2). Analysis of the same threeThe American Journal of Humanmicrosatellites in the family of indi-
vidual 2, who carries the same de
novo PDE10A change, indicated thatthe mutation arose on a different background haplotype
(Figure S2). De novo mutations in PDE10A have not
been observed in control individuals,12–16 and neither
p.Phe300Leu nor p.Phe334Leu is listed in the ExAC
Browser (last accessed in November 2015) or in-house data-
bases, together containing ~75,000 individuals. PDE10A
has a residual variation intolerance score17 of 0.98, indi-
cating that it belongs to the top 8.8% of the human
genes most intolerant to genetic variation. Furthermore,
constraint metrics reported in the ExAC Browser indicate
that PDE10A is intolerant to both loss-of-function (proba-
bility of loss-of-function intolerance ¼ 1.00) and missense
(Z score ¼ 3.78) mutations.18 Interspecies alignment of
protein sequences generated with Clustal Omega19 re-
vealed that the substitutions affect amino acid residues
that are completely conserved down to invertebrate spe-
cies (Figure 2B).
Next, we explored the regional expression of PDE10A
in the normal adult human brain. To this end, we used mi-
croarray data (Affymetrix Exon 1.0 ST) from human post-
mortem brain tissue collected by the UK Human Brain
Expression Consortium as previously described.20 This
analysis showed exceptionally high expression in the puta-
men (Figure 3A), which is consistent with the data avail-
able in the Allen Mouse Brain Atlas21 (Figures 3B and 3C)
and previous work demonstrating high and selective
PDE10A expression in human striatum at both the RNA
and protein levels.22,23
PDE10A encodes a member of the cyclic nucleotide
(cNMP) phosphodiesterase (PDE) family, consisting of 21
different proteins grouped into 11 sub-families according
to their affinity for the type of cNMP (cyclic adenosine
monophosphate [cAMP] and/or cyclic guanosine mono-
phosphate [cGMP]), cellular regulation, and tissue distri-
bution.24 cNMPs are ubiquitously localized intracellular
second messengers, which modulate a broad range
of cellular functions and pathways.25 The intracellularGenetics 98, 763–771, April 7, 2016 765
Figure 2. Pedigrees, PDE10AMutation Analysis, Interspecies Alignment, Schematic Representation of PDE10A, In Silico Modeling of
the 3D Structure of the PDE10A GAF-B Domain, and Functional Studies of the Identified PDE10A Substitutions
(A) Pedigrees of the three individuals carrying the de novo PDE10A mutations and Sanger sequencing confirmation of the mutations.
The following abbreviations are used: WT, homozygous wild-type alleles; and M, heterozygous PDE10A mutations.
(B) Interspecies alignment performed with Clustal Omega shows the complete conservation down to invertebrates of the amino acid
residues affected by the substitutions. Asterisks indicate invariant residues (full conservation), whereas colons and periods represent
strong and moderate similarities, respectively.
(legend continued on next page)
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Figure 3. Summary of PDE10A mRNA Expression in the Human and Mouse Brain
(A) Boxplots of PDE10AmRNA expression levels in ten adult brain regions (source: BRAINEAC, seeWeb Resources). The expression levels
are based on exon array experiments and are plotted on a log2 scale (y axis). This dataset was generated with Affymetrix Exon 1.0 ST
arrays and brain tissue originating from 134 control individuals, collected by the Medical Research Council Sudden Death Brain and Tis-
sue Bank and the SunHealth Research Institute, an affiliate of SunHealth Corporation.20 This plot shows significant variation in PDE10A
expression across the ten brain regions analyzed, such that expression is higher in the putamen than in any other region. Abbreviations
are as follows: PUTM, putamen; FCTX, frontal cortex; TCTX, temporal cortex; OCTX, occipital cortex; HIPP, hippocampus; SNIG, sub-
stantia nigra; MEDU, medulla (specifically the inferior olivary nucleus); WHMT, intralobular white matter; THAL, thalamus; CRBL, cere-
bellar cortex; and N, number of samples analyzed for each brain region.
(B and C) PDE10A expression in the mouse brain in (B) sagittal and (C) coronal sections. PDE10A was very highly and selectively ex-
pressed in the striata and in the olfactory tubercula. Images were obtained from the Allen Mouse Brain Atlas (2015 Allen Institute
for Brain Science). Expression intensity is color coded and ranges from low (blue) to moderate (green, yellow) to high (red) intensity.concentration of cNMPs is tightly regulated through a fine
balance between their synthesis (controlled by the activity
of adenylyl and guanylyl cyclases26,27) and degradation
(mediated by PDEs, which hydrolyze the cNMPs into their
corresponding monophosphate nucleoside28). PDEs func-
tion as homodimers (the dimer interface extends over
the entire length of the molecule), and all share a highly
similar catalytic domain located in the C-terminal portion
of the protein. Conversely, the N-terminal portion, which
contains the regulatory domains, is variable and differs
between different PDE families.29 PDE10A contains two
N-terminal domains, GAF-A and GAF-B, of which the latter
binds to cAMP (Figure 2C).30,31 cAMP binding increases
the enzyme activity of the PDE10A catalytic domain.32
Although details of the GAF-B-dependent modulation of
PDE10A enzyme activity are currently unclear, a general(C) A schematic representation of PDE10A shows its organization in
N-terminal portion of the protein and the catalytic domain in the
both located in the GAF-B domain, which binds to cAMP.
(D) In silico modeling of the 3D structure of the GAF-B domain bind
generated with PDB: 2ZMF. The variant residues Phe300 and Phe33
respectively, forming the floor of the cAMP binding pocket, are show
close proximity to the cAMP molecule and are therefore likely to pla
(E) The p.Phe300Leu and p.Phe334Leu substitutions cause a loss of sti
The effect of cyclic nucleotides binding to the GAF-B domain on PDE a
WT and mutant PDE10As were incubated in the presence of variou
point represents the mean5 SEM of three independent experiment
The Ammechanism for the regulation of all PDEs has been postu-
lated. In the non-activated state, the dimerized catalytic
domains are packed against each other at the dimer inter-
face, occluding the catalytic pockets. The binding of
cAMP to the GAF-B domain induces a rotating movement
of the catalytic domains, enabling substrate access to the
catalytic pockets and a consequent increase in cNMP
hydrolysis.33
The crystal structure of the PDE10A-GAF-B domain and
its interaction with cAMP has been elucidated and consists
of a six-stranded anti-parallel b sheet (b3, b2, b1, b6, b5,
and b4) sandwiched between a three-helix bundle (a1,
a2, and a5) on one side and three short helices (a3, a4,
and 310) on the other side.
34 The cAMP molecule is almost
completely buried deep in a tight binding pocket, the floor
of which is formed by the b sheets and the roof of which isthree domains: the regulatory GAF-A and GAF-B domains in the
C terminus. The p.Phe300Leu and p.Phe334Leu substitutions are
ing pocket and its interaction with the cAMP (shown in blue) was
4 and their aromatic side chains, located in the b1 and b3 sheets,
n in red and cyan, respectively. Both residues are located in very
y an essential role in nucleotide binding.
mulatory effect of the GAF-B domain on PDE10A catalytic activity.
ctivity was evaluated viameasurement of the enzyme activity after
s concentrations of 1-NO-cAMP and 70 nM [3H]cGMP. Each data
s.
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formed by two a helices (a3 and a4). Importantly, the
amino acids Phe300 and Phe334 are located in the b1
and b3 sheets, respectively, and are positioned deep in
the cAMP binding pocket of GAF-B in very close proximity
to the cAMPmolecule (Figure 2D). It is therefore postulated
that the substitutions severely affect the morphology of
the GAF-B binding pocket and/or alter its affinity for cAMP.
To assess the functional effect of the identified PDE10A
substitutions in vitro, we investigated whether they affect
(1) PDE basal enzyme activity and/or (2) the stimulatory ef-
fect on PDE catalytic activity mediated by cAMP binding to
the GAF-B domain. cDNA for human PDE10A (GenBank:
NM_001130690.2) was used as a template, and mutant
constructs (c.898T>C [p.Phe300Leu] and c.1000T>C
[p.Phe334Leu]) were inserted by site-directed mutagenesis.
Wild-type (WT) and mutant constructs were cloned into
the pcDNA3.1(þ)neo vector (Thermo Fisher Scientific)
and transfected into COS-7 cells (European Collection of
Authenticated Cell Cultures). In vitro PDE enzyme activity
was measured with a scintillation-proximity-assay (SPA)-
based method.35 In this assay, the product of the PDE
reaction, either [3H]-labeled AMP or GMP, binds directly
to yttrium silicate PDE SPA beads (GE Healthcare), result-
ing in light emission. Reactions for kinetic studies were
conducted with a mixture of [3H]-labeled and unlabeled
cAMP or cGMP together with either WT or mutant
PDE10A-expressing COS-7 cell membrane fractions. These
experiments showed no significant difference betweenWT
and mutant PDE10As (Figure S3), suggesting that both
p.Phe300Leu and p.Phe334Leu do not substantially affect
basal PDE10A enzyme activity.
We then explored whether the identified substitutions
affect the stimulatory properties of cAMP binding to the
GAF-B domain. We conducted experiments by using only
[3H]cGMP as a substrate (to avoid the binding of [3H]
cAMP substrate to the GAF-B domain) and the cAMP
analog 1-NO-cAMP (Biolog Life Science Institute), whose
selectivity for the GAF-B domain over the catalytic site is
~283 higher than that of cAMP (247-fold for 1-NO-cAMP
versus 8.7-fold for cAMP).35 These experimental condi-
tions were chosen because, on the one hand, cAMP acti-
vates PDE10A enzyme activity via its binding to GAF-B,
and on the other hand, cAMP competes at the catalytic
domain with radio-labeled substrates and thus inhibits
their degradation.35 1-NO-cAMP markedly increased
(approximately 2.7-fold over the basal levels) the enzyme
activity of WT PDE10A, whereas this effect was almost
completely lost for both mutant PDE10As (Figure 2E).
These experiments demonstrate that p.Phe300Leu and
p.Phe334Leu severely affect the positive regulatory mech-
anism of cAMP binding to the GAF-B domain on PDE cat-
alytic activity.
PDEs have previously been implicated in the pathogen-
esis of neurodegenerative disorders, such as Parkinson
disease and Huntington disease.36 Mutations in PDE8B
(MIM: 603390), a gene highly expressed in the brain and
especially in the putamen, causes autosomal-dominant768 The American Journal of Human Genetics 98, 763–771, April 7, 2striatal degeneration (ADSD [MIM: 609161]), a disease
that clinically manifests with adult-onset parkin-
sonism.37,38 Although the reported MRI abnormalities
observed in subjects with ADSD are slightly different
from those observed in our individuals, it is striking that
both diseases are caused by alterations in PDEs, which
lead to clearly visible, largely symmetric, striatal MRI signal
abnormalities. Furthermore, the fact that two PDEs are
now directly linked to a basal ganglia disease might point
toward a crucial role of PDEs in these types of disorders.
The latter is of great interest given the pharmacological
potential to manipulate PDE activity. Given its high and
selective presence in striatal MSNs, PDE10A is a primary
target in pharmacological research for diseases where
dysregulation of striatal circuits is believed to be crucial
(e.g., psychosis, Huntington disease, substance abuse,
and Parkinson disease).39
According to the classic model of basal ganglia motor cir-
cuits, chorea mainly results from dysregulation of MSN ac-
tivity.40 Importantly, modulation of MSN activity is largely
dependent on cAMP signaling.41 cAMP synthesis, and thus
indirectly its signaling, is promoted by stimulation of the
G-protein-coupled dopamine receptor D1 and adenosine
receptor A2, whereas synthesis is inhibited by dopamine
stimulation of dopamine receptor D2.42 The G protein
Gaolf positively couples receptors D1 and A2 to the activa-
tion of adenylate cyclase 5 (AC5), the main molecule
responsible for cAMP production in MSNs.43 Interestingly,
mutations in the genes encoding Gaolf (GNAL [MIM:
139312]) and AC5 (ADCY5) have been identified as a cause
of primary dystonia44 and chorea,45,46 respectively.
Mechanistically, ADCY5 mutations seem to increase
AC5 activity and consequently cause raised intracellular
cAMP levels in cellular models.47 Given that pathogenic
mutations in both PDE10A and ADCY5 cause chorea
(even though PDE10A and AC5 exert opposite effects on
cAMP levels), one would expect that the p.Phe300Leu
and p.Phe334Leu variants exert a deleterious effect on
PDE enzyme activity. Recent studies have suggested that
PDE10A has two functional states: ‘‘active’’ and ‘‘super-
active.’’32,48 In the presence of high intracellular levels of
cAMP, its binding to the GAF-B domain would stimulate
the PDE catalytic activity, switching PDE10A from the
‘‘active’’ to the ‘‘super-active’’ state. In light of this,
PDE10A might function as a ‘‘brake’’ for MSN activation.
Our functional studies showed that pathogenic PDE10A
mutations located in the GAF-B domain severely disrupt
this positive regulatory mechanism without affecting
the basal PDE enzyme activity. These mutations might
therefore have a strong impact on the in vivo regulation
of MSN activity, especially when MSNs are activated by
high levels of cAMP. Given the homodimerized structure
of PDE10A, the mutant proteins could exert a dominant-
negative effect on the activity of the WT protein.
In conclusion,wehave demonstrated that de novo domi-
nant mutations in PDE10A are the cause of a uniquemove-
ment disorder characterized by benign childhood-onset016
chorea and typical MRI abnormalities of the striatum. Of
note, screening of a cohort of ~60 individuals with a BHC-
like syndrome and lacking mutations inNKX2-1 (clinically
resembling subjects with PDE10A mutations but with
normal brainMRI ) did not reveal any additionalmutations
in PDE10A. The latter suggests that PDE10A-related chorea
might represent a distinct genetic clinico-radiological en-
tity. Mutational screening of additional cohorts with such
MRI abnormalities is warranted for further defining the
clinical spectrum associated with PDE10A mutations.
Furthermore, it will be important to establish whether the
observation of parkinsonism with nigrostriatal degenera-
tion in individual 3 is coincidental or whether individuals
with de novo PDE10A mutations are also at an increased
risk of developing degeneration of nigral neurons. In this
regard, recent work has demonstrated that striatal reduc-
tion of PDE10A levels is associated with the duration and
severity of Parkinson disease.49 With the previous discov-
eries of mutations in GNAL, PDE8B, and ADCY5, and now
PDE10A, there is accumulating evidence that intracellular
cAMP signaling in striatal MSNs is crucial for normal activ-
ity of basal ganglia circuitry and that disruptions thereof
play an important role in the pathophysiology of move-
ment disorders. Our results highlight pharmacological
manipulation of cAMP levels in MSNs as a promising
therapeutic strategy for the treatment of chorea and other
movement disorders.Supplemental Data
Supplemental Data include three figures and can be found
with this article online at http://dx.doi.org/10.1016/j.ajhg.2016.
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